{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI were not available due to censoring.","groupId":"OG000","lowerLimit":"63.5","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was not available due to censoring.","groupId":"OG001","lowerLimit":"45.0","upperLimit":"NA","value":"75.04"},{"comment":"Median and upper limit of 95% CI were not available due to censoring.","groupId":"OG002","lowerLimit":"45.8","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"94"}],"units":"Participants"}],"description":"PFS was defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression were met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP was defined as: \\>=15% and \\<30% blasts in peripheral blood or bone marrow or \\>=20% basophils in peripheral blood or bone marrow or \\>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \\<30% blasts) or \\<100\\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP was defined as: \\>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"MEDIAN","populationDescription":"All randomized participants were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 8.9 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}